financetom
Business
financetom
/
Business
/
Why GoPro Shares Are Gaining Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why GoPro Shares Are Gaining Today
Jul 9, 2024 11:08 AM

GoPro, Inc ( GPRO ). shares are trading higher on Tuesday.

The company announced a fresh distribution collaboration with SoftBank Group’s (OTC:SFTBY) SB C&S Corporation in Japan, leveraging one of the region’s largest sales networks to market GoPro ( GPRO ) products.

“Through SB C&S, we’re continuing the expansion of our global retail presence, ensuring that GoPro ( GPRO ) products are more widely available to customers in Japan and improving our in-store merchandising and brand exposure,” said Dean Jahnke, GoPro’s Senior Vice President of Global Sales and Channel Marketing.

Also Read: Netflix ‘Positively Positioned For Operating Momentum’: Analyst Sees ‘Normalization Of Streaming Wars’

Under the agreement, SB C&S can now offer its retail customers in Japan the complete lineup of GoPro ( GPRO ) cameras and accessories, expanding access to the latest innovations and products from GoPro ( GPRO ).

SB C&S will distribute GoPro ( GPRO ) cameras and accessories across Japan, including SoftBank stores, Yodobashi, and Yamada.

They’ll enhance retail displays and offer training to improve customer shopping experiences for GoPro ( GPRO ) products.

In May, the company announced a large-scale merchandising rollout and sales program at Best Buy Co., Inc. ( BBY ) .

Price Action: GPRO shares are trading higher by 7.39% to $1.525 at last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Read Next:

This Medical Stock Soared Over 80% In Pre-Market After Advancing Gene Therapy Program For ALS, Alzheimer’s And Parkinson’s Diseases

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
Nov 5, 2025
MIAMI--(BUSINESS WIRE)-- World Kinect Corporation ( WKC ) today announced that it has completed its previously announced acquisition of the Trip Support Services (TSS) division of Universal Weather and Aviation. Universal Weather, headquartered in Houston, Texas, has been a pioneer in trip support services with deep expertise in international travel regulations, logistics, and supply chain management. Its trip support business...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
Copyright 2023-2026 - www.financetom.com All Rights Reserved